Starting Technology in At Risk Type 1 Diabetes Study
Starting Technology in At Risk Type 1 Diabetes (STAR-T1D) Study
- Diabetes Mellitus, Type 1
At a glance
- Phase
- Phase not stated
- Study type
- Interventional
- Sponsor
- University of California, Los Angeles
- Enrolment target
- 40
- Started
- 5 September 2024
- Main results due
- 31 January 2027
- Study sites
- 3
- Registry updated
- 25 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Type 1 Diabetes * A1c ≥ 8.0% * Not insulin pump user * Primary language of English or Spanish * Have medical insurance coverage Exclusion Criteria: * No measured A1c in the past year * Have comorbidities that can result in inaccurate hemoglobin A1c * Have cognitive, physical or mental impairment precluding diabetes technology use * Limited life expectancy (\<1 year) * Pregnancy
What this study is about
In the sponsor’s own words, from the registry.
Diabetes technology has revolutionized T1D management, disparities in technology access are evident among racial-ethnic minorities, patients with lower socioeconomic status and those with poorly controlled T1D (A1c\>8.5%). In order to examine whether diabetes technology can reduce diabetes care burdens and enhance outcomes among some of highest need patients, diabetes technology clinical trials must be expanded beyond the very select populations included in studies thus far (ie., mostly White, higher SES). Therefore, the investigators propose to perform a pilot RCT of hybrid closed-loop insulin pump therapy (HCL) in 40 diverse adult patients with poorly controlled T1D (HbA1c \>8.5%) from the largest academic and safety net health systems in the Los Angeles region to determine the feasibility of a RCT in this population and identify facilitators and barriers of effective use of closed loop insulin pump therapy in patients with poorly controlled T1D.
Study sites(3)
UCLA
Santa Monica, California, United States
Recruiting
Olive View-UCLA Medical Center
Sylmar, California, United States
Recruiting
Harbor-UCLA Medical Center
Torrance, California, United States
Recruiting
Showing 3 of 3 sites. 3 of the 3 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT06453928. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me